Search Results

Cantabio Pharmaceuticals, Inc. announced that The Michael J. Fox Foundation for Parkinson’s Research has awarded the Company a major grant for a project entitled “Development of Cell-penetrant DJ-1 Protein as a Therapeutic Candidate for Treatment of Parkinson’s Disease.” This grant supports the Company’s ongoing cell-penetrant DJ-1 protein replacement therapeutic program.

Cantabio Pharmaceuticals, Inc. announced that The Michael J. Fox Foundation for Parkinson’s Research has awarded the Company a major grant entitled “Quantification of Cys106 of DJ-1 in Distinct Redox States in Parkinson’s Patients’ iPSC-derived Dopaminergic Neurons, Postmortem Brain Tissue and Plasma as a Potential Biomarker of Parkinson’s Disease”.

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Nika Pharmaceuticals, Inc. introduces its plans to develop the company into a sustainable business project that will consistently grow, bring good profits and provide dividends to its shareholders.

Bexion Pharmaceuticals, Inc. announced that the Company will present at the 2024 Biotechnology Innovation Organization International Convention taking place June 3-6, 2024, in San Diego, California.

Future Pak, LLC and its affiliates announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. in a good faith effort to acquire all outstanding shares of Vanda.